# Trial of NanoPac Focal Therapy for Prostate Cancer

> **NCT04221828** · PHASE2 · TERMINATED · sponsor: **NanOlogy, LLC** · enrollment: 1 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma
- Prostate Cancer Adenocarcinoma
- Prostatic Neoplasm
- Urogenital Neoplasms
- Genital Neoplasms, Male
- Localized Cancer

## Interventions

- **DRUG:** NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension

## Key facts

- **NCT ID:** NCT04221828
- **Lead sponsor:** NanOlogy, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-20
- **Primary completion:** 2021-01-27
- **Final completion:** 2021-02-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221828, "Trial of NanoPac Focal Therapy for Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04221828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*